Trial Profile
A pilot study assessing safety and antiretroviral activity of intravenously administered LTB4 [leukotriene B4] in HIV-1 infected adults with a CD4 count greater than 250 cells/mm3 and a viral load greater than 5,000 copies/mL, and who have not received antiretroviral therapy within two months
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Leukotriene B4 (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors LTB4 AB
- 18 Nov 2006 Status change
- 26 Oct 2006 New trial record.